Literature DB >> 33266287

The Health-Related Quality of Life of Sarcoma Patients and Survivors in Germany-Cross-Sectional Results of a Nationwide Observational Study (PROSa).

Martin Eichler1,2, Leopold Hentschel2, Stephan Richter1, Peter Hohenberger3, Bernd Kasper4, Dimosthenis Andreou5,6, Daniel Pink6,7, Jens Jakob8, Susanne Singer9, Robert Grützmann10, Stephen Fung11, Eva Wardelmann12, Karin Arndt13, Vitali Heidt14, Christine Hofbauer2,15, Marius Fried16, Verena I Gaidzik17, Karl Verpoort18, Marit Ahrens19, Jürgen Weitz2,20, Klaus-Dieter Schaser2,15, Martin Bornhäuser1,2, Jochen Schmitt2,21, Markus K Schuler1,22.   

Abstract

Sarcomas are rare cancers with high heterogeneity in terms of type, location, and treatment. The health-related quality of life (HRQoL) of sarcoma patients has rarely been investigated and is the subject of this analysis. Adult sarcoma patients and survivors were assessed between September 2017 and February 2019 in 39 study centers in Germany using standardized, validated questionnaires (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)). Associated factors were analyzed exploratively using multivariable linear regressions. Among 1113 patients, clinically important limitations and symptoms were most pronounced in emotional (63%, 95% CI 60-66%), physical (60%, 95% CI 57-62%), role functioning (51%, 95% CI 48-54%), and pain (56%, 95% CI 53-59%) and fatigue (51%, 95% CI 48-54%). HRQoL differed between tumor locations with lower extremities performing the worst and sarcoma types with bone sarcoma types being most affected. Additionally, female gender, higher age, lower socioeconomic status, recurrent disease, not being in retirement, comorbidities, and being in treatment were associated with lower HRQoL. Sarcoma patients are severely restricted in their HRQoL, especially in functioning scales. The heterogeneity of sarcomas with regard to type and location is reflected in HRQoL outcomes. During treatment and follow-up, close attention has to be paid to the reintegration of the patients into daily life as well as to their physical abilities and emotional distress.

Entities:  

Keywords:  clinically important restrictions and symptoms; health-related quality of life; observational study; rare disease; sarcoma

Year:  2020        PMID: 33266287     DOI: 10.3390/cancers12123590

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  7 in total

1.  Utilization of Interdisciplinary Tumor Boards for Sarcoma Care in Germany: Results from the PROSa Study.

Authors:  Martin Eichler; Dimosthenis Andreou; Henriette Golcher; Leopold Hentschel; Stephan Richter; Peter Hohenberger; Bernd Kasper; Daniel Pink; Jens Jakob; Hany Ashmawy; Simone Hettmer; Armin Tuchscherer; Matthias Grube; Vitali Heidt; Christina Jentsch; Jessica Pablik; Eva Wardelmann; Karl-Friedrich Kreitner; Ulrich Kneser; Carolin Tonus; Pauline Wimberger; Olaf Schoffer; Peter Reichardt; Markus Wartenberg; Maria Eberlein-Gonska; Martin Bornhäuser; Jochen Schmitt; Markus K Schuler
Journal:  Oncol Res Treat       Date:  2021-04-22       Impact factor: 2.825

2.  Randomized Prospective Trial Exploring the Impact of Structured Journaling in Patients With Sarcoma on the Management of Treatment-Related Adverse Events.

Authors:  N J Speece; Menglin Xu; Gabriel Tinoco; David A Liebner; James L Chen
Journal:  JCO Oncol Pract       Date:  2021-09-24

3.  Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes.

Authors:  Anne-Rose W Schut; Emma Lidington; Milea J M Timbergen; Eugenie Younger; Winette T A van der Graaf; Winan J van Houdt; Johannes J Bonenkamp; Robin L Jones; Dirk J Grünhagen; Stefan Sleijfer; Cornelis Verhoef; Spyridon Gennatas; Olga Husson
Journal:  Cancers (Basel)       Date:  2022-06-16       Impact factor: 6.575

4.  A Multicenter, Prospective, Observational Study to Assess the Clinical Activity and Impact on Symptom Burden and Patients' Quality of Life in Patients with Advanced Soft Tissue Sarcomas Treated with Trabectedin in a Real-World Setting in Greece.

Authors:  Stefania Kokkali; Ioannis Boukovinas; Epaminondas Samantas; Pavlos Papakotoulas; Ilias Athanasiadis; Charalampos Andreadis; Parisis Makrantonakis; Georgios Samelis; Eleni Timotheadou; Georgios Vassilopoulos; Christos Papadimitriou; Dimitrios Tzanninis; Alexandros Ardavanis; Ioannis Kotsantis; Kiki Karvounis-Marolachakis; Theodora Theodoropoulou; Amanda Psyrri
Journal:  Cancers (Basel)       Date:  2022-04-08       Impact factor: 6.575

5.  The Therapeutic Role of Plastic and Reconstructive Surgery in the Interdisciplinary Treatment of Soft-Tissue Sarcomas in Germany-Cross-Sectional Results of a Prospective Nationwide Observational Study (PROSa).

Authors:  Benjamin Thomas; Amir K Bigdeli; Steffen Nolte; Emre Gazyakan; Leila Harhaus; Oliver Bischel; Burkhard Lehner; Gerlinde Egerer; Gunhild Mechtersheimer; Peter Hohenberger; Raymund E Horch; Dimosthenis Andreou; Jochen Schmitt; Markus K Schuler; Martin Eichler; Ulrich Kneser
Journal:  Cancers (Basel)       Date:  2022-09-02       Impact factor: 6.575

6.  The association of Health-Related Quality of Life and 1-year-survival in sarcoma patients-results of a Nationwide Observational Study (PROSa).

Authors:  Martin Eichler; Susanne Singer; Leopold Hentschel; Stephan Richter; Peter Hohenberger; Bernd Kasper; Dimosthenis Andreou; Daniel Pink; Jens Jakob; Robert Grützmann; Stephen Fung; Eva Wardelmann; Karin Arndt; Vitali Heidt; Sergio Armando Zapata Bonilla; Verena I Gaidzik; Helena K Jambor; Jürgen Weitz; Klaus-Dieter Schaser; Martin Bornhäuser; Jochen Schmitt; Markus K Schuler
Journal:  Br J Cancer       Date:  2022-01-20       Impact factor: 9.075

7.  Financial toxicity in sarcoma patients and survivors in Germany: results from the multicenter PROSa study.

Authors:  Matthias Büttner; Susanne Singer; Leopold Hentschel; Stephan Richter; Peter Hohenberger; Bernd Kasper; Dimosthenis Andreou; Daniel Pink; Kathy Taylor; Karin Arndt; Martin Bornhäuser; Jochen Schmitt; Markus K Schuler; Martin Eichler
Journal:  Support Care Cancer       Date:  2021-07-11       Impact factor: 3.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.